Hashimoto T, Nakayama S, Fukkuhara T, Okuno T, Takamine Y, Konishi Y, Tani T, Kajiwara T
1st Department of Surgery, Kobe City General Hospital, Japan.
Hepatogastroenterology. 1994 Apr;41(2):144-9.
The subjects involved in the present study were 113 patients with hepatocellular carcinomas who had undergone hepatectomy in our hospital during the past 10 years. During the surveillance, 79 of the 113 patients (69.9%) had recurrence in the residual liver. The cumulative non-recurrence rate at 2 and 5 years was 48.4% and 18.1%, respectively and the cumulative survival rate at 2 and 5 years was 83.8% and 47.5%, respectively. The recurrence in the residual liver tended to occur in the group with the larger tumor size, in the single nodular surrounding proliferative types and in the aneuploid types. There were no differences in the recurrence rate and state relating to the operative procedure. To improve the prognosis of hepatocellular carcinoma, it is necessary to consider the hepatic functional reserve after hepatectomy, and to make plans for multidisciplinary therapy, including such further treatment as transcatheter arterial embolization, infusion chemotherapy and preoperative percutaneous ethanol injection.
本研究的对象为过去10年内在我院接受肝切除术的113例肝细胞癌患者。在随访期间，113例患者中有79例（69.9%）在残余肝脏出现复发。2年和5年的累积无复发率分别为48.4%和18.1%，2年和5年的累积生存率分别为83.8%和47.5%。残余肝脏复发倾向于发生在肿瘤体积较大、单结节周围增殖型和非整倍体类型的患者中。复发率和复发状态与手术方式无关。为改善肝细胞癌的预后，有必要考虑肝切除术后的肝功能储备，并制定多学科治疗计划，包括经导管动脉栓塞、灌注化疗和术前经皮乙醇注射等进一步治疗。
